<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167984">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01673399</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000278-49</org_study_id>
    <nct_id>NCT01673399</nct_id>
  </id_info>
  <brief_title>Oxytocin Antagonist in Patients With Repeated Failure of Implantation</brief_title>
  <official_title>Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Jan Palfijn Gent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onze Lieve Vrouw  Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ Jan Palfijn Gent</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators compare the usual way of embryo transfer (without
      medication) with an embryo transfer while administering oxytocine antagonist. This to
      improve implantation and increase the pregnancy rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>implantation rate</measure>
    <time_frame>16 days from eggretrieval</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of patients that show a positive blood pregnancy test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of patients with an ongoing first trimester pregnancy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Repeated Implantation Failure</condition>
  <arm_group>
    <arm_group_label>Atosiban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.</description>
    <arm_group_label>Atosiban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IVF/ ICSI patients below 38 years

          -  2e to 6e IVF-cycle

        Exclusion Criteria:

          -  patients with endocrinological diseases or problems
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wim Decleer, gynecologist</last_name>
    <phone>0032 9 3259220</phone>
    <email>wim.decleer@janpalfijngent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Devroey, professor</last_name>
    <phone>0032 9 2248070</phone>
    <email>ivf.studie@janpalfijngent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Jan Palfijn</name>
      <address>
        <city>Gent</city>
        <state>Oost-vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim Decleer, gynecologist</last_name>
      <phone>0032 9 2243024</phone>
      <email>wim.decleer@janpalfijngent.be</email>
    </contact>
    <contact_backup>
      <phone>0032 9 2248850</phone>
      <email>ivf.centrum@janpalfijngent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Wim Decleer, gynecologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 27, 2012</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Jan Palfijn Gent</investigator_affiliation>
    <investigator_full_name>Dr. Decleer Wim</investigator_full_name>
    <investigator_title>gynecologist</investigator_title>
  </responsible_party>
  <keyword>repeated implantation failure</keyword>
  <keyword>atosiban</keyword>
  <keyword>pregnancy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Atosiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
